The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Statsenko M.E.

Volgogradskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Turkina S.V.

Volgogradskiĭ gosudarstvennyĭ meditsinskiĭ universitet Minzdrava Rossii

Ermolenko A.A.

Volgograd State Medical University, Ministry of Health of Russia, Volgograd, Russia

Unsolved problems of cytoprotective therapy in patients with coronary heart disease

Authors:

Statsenko M.E., Turkina S.V., Ermolenko A.A.

More about the authors

Journal: Therapeutic Archive. 2015;87(12): 101‑106

DOI: 10.17116/terarkh20158712101-106

Read: 2078 times

Download PDF (RU)
Contact the author
Table of contents

UNSOLVED PROBLEMS OF CYTOPROTECTIVE THERAPY IN PATIENTS WITH CORONARY HEART DISEASE
UNSOLVED PROBLEMS OF CYTOPROTECTIVE THERAPY IN PATIENTS WITH CORONARY HEART DISEASE

To cite this article:

Statsenko ME, Turkina SV, Ermolenko AA. Unsolved problems of cytoprotective therapy in patients with coronary heart disease. Therapeutic Archive. 2015;87(12):101‑106. (In Russ.)
https://doi.org/10.17116/terarkh20158712101-106

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Refralon for drug-induced cardioversion of atrial fibrillation in patients with coro­nary artery disease. Russian Cardiology Bulletin. 2024;(4-2):188-196
Inci­dence of diseases of the circulatory system in the working-age popu­lation of the Ural Fede­ral District in 2012—2022. Russian Journal of Preventive Medi­cine. 2025;(1):24-29
Clinical outcomes after transcatheter aortic valve implantation in patients with concomitant coro­nary artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):45-52
Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chro­nic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60
Adipocytokines as a predictor of the risk of adve­rse outcomes in patients with coro­nary heart disease and abdo­minal obesity after percutaneous coro­nary inte­rvention. Russian Journal of Preventive Medi­cine. 2025;(2):38-45
The Rela­tionship of obstructive sleep apnea with paro­xysmal atrial fibrillation in women suffered coro­nary heart disease and arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(2):61-66
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
10-year dyna­mics of cardiovascular status in combination with coro­nary angiography data in men of working age in the Arctic region of resi­dence and the south of the Tyumen region. Russian Journal of Preventive Medi­cine. 2025;(4):30-38
Coro­nary artery disease in young women: a modern view on the problem. Russian Cardiology Bulletin. 2025;(2):5-12
Serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in coro­nary artery disease patients. Russian Cardiology Bulletin. 2025;(2):13-19
Abstract:

The paper gives data on the proven efficiency of myocardial cytoprotection with the pFOX inhibitors trimetazidine and meldonium for coronary heart disease. However, no algorithm has been defined for their differentiated use at different ischemic remodeling stages in these patients in terms of the mechanism of metabolic effects. Sequential use of meldonium and trimetazidine in different periods of acute and chronic myocardial ischemia may become one of the possible ways to increase the efficacy of the pFOX inhibitors.

Keywords:

coronary heart disease
cardioprotection
pFOX inhibitors

Authors:

Statsenko M.E.

Volgogradskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Turkina S.V.

Volgogradskiĭ gosudarstvennyĭ meditsinskiĭ universitet Minzdrava Rossii

Ermolenko A.A.

Volgograd State Medical University, Ministry of Health of Russia, Volgograd, Russia

Close metadata

References:

  1. Takii T, Yasuda S, Takahashi J et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study. Circ J. 2010;74(1):93-100. doi:10.1253/circj.cj-09-0619.
  2. Roger VL, Go AS, Lloyd-Jones DM et al. Executive summary: heart disease and stroke statistics — 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.  doi:10.1161/cir.0b013e3182456d46.
  3. Hausenloy DJ, Erik Botker H, Condorelli G et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013;98(1):7-27.  doi:10.1093/cvr/cvt004.
  4. Lecour S, Bøtker Hans E, Condorelli G et al. ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014;104(3):399-411.  doi:10.1093/cvr/cvu225.
  5. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res. 2008;77(2):334-343.  doi:10.1093/cvr/cvm005.
  6. Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2010;12(4):537-777.  doi:10.1089/ars.2009.2531.
  7. Stanley, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093-1129. doi:10.1152/physrev.00006.2004.
  8. Astashkin E.I., Glezer M.G. Metabolicheskie tsitoprotektory i mekhanizmy ikh deistviya. Energeticheskii obmen serdtsa. 2009;1:12.
  9. Van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac bum-out syndrome? Cardiovasc Res. 2004;61(2):218-226.  doi:10.1016/j.cardiores.2003.11.014.
  10. Mikhin V.P. Kardiotsitoprotektory — novoe napravlenie klinicheskoi kardiologii. Arkhiv vnutrennei meditsiny. 2011;1:21-28.
  11. Ashrafian H, Frenneaux MP, Lionel H et al. Metabolic Mechanisms in Heart Failure. Circulation. 2007;116:434-448.  doi:10.1161/circulationaha.107.702795.
  12. Dzerve V.Ya., Kalvin'sh I.Ya. Mildronat v kardiologii. Obzor issledovanii. Riga; 2013.
  13. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mito chondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:487-489.  doi:10.1161/01.res.86.5.580.
  14. Napoli D, Taccardi A, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91:161-165.  doi:10.1136/hrt.2003.031310.
  15. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25:634-641.
  16. Statsenko M.E., Sporova O.E. Vliyanie trimetazidina na funktsional'noe sostoyanie serdtsa, pochek i kachestvo zhizni v kompleksnoi dlitel'noi terapii khronicheskoi serdechnoi nedostatochnosti u patsientov pozhilogo vozrasta. Kardiovaskulyarnaya terapiya i profilaktika. 2005;4(5):57-61.
  17. The EMIP-FR Group. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. Eur Heart J. 2000;21:1537-1546. doi:10.1053/euhj.1999.2439.
  18. Statsenko M.E., Turkina S.V., Shilina N.N. Rol' rFox-ingibitorov v lechenii bol'nykh s ostroi ishemiei miokarda. Terapevticheskii arkhiv. 2014;1:54-59.
  19. Gordeev I.G., Luchinkina E.E., Lyusov V.A. Antioksidantnyi effekt kardioprotektora mildronata u patsientov, podvergshikhsya koronarnoi revaskulyarizatsii. Rossiiskii kardiologicheskii zhurnal. 2009;1(75):31-37.
  20. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiology. 2006;98:14-18.  doi:10.1016/j.amjcard.2006.07.004.
  21. Miles JM, Nelson RH. Contribution of triglyceride-rich lipoproteins to plasma free fatty acids. Horm Metab Res. 2007;39(10):726-729.  doi:10.1055/s-2007-990273.
  22. Leichman JG, Aguilar D, King TM et al. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am J Clin Nutr. 2006;84(2):336-341. 
  23. Lopaschuk GD, Ussher JR, Folmes C et al. Myocardial Fatty Acid Metabolism in Health and Disease. Physiol Rev. 2010;90:207-258.  doi:10.1152/physrev.00015.2009.
  24. Statsenko M.E., Turkina S.V., Tolstov S.N. Mesto r-fox ingibitorov svobodnykh zhirnykh kislot v kombinirovannoi terapii serdechno-sosudistykh oslozhnenii u bol'nykh sakharnym diabetom 2 tipa. Rossiiskii kardiologicheskii zhurnal. 2011;2(88):102-110.
  25. Statsenko M.E., Turkina S.V. Metabolicheskaya kardioprotektsiya pri ishemicheskoi bolezni serdtsa: itogi i perspektivy. Lechashchii vrach. 2012;7:62-67.
  26. Statsenko M.E., Turkina S.V., Lempert B.A., Evtereva E.D. Ispol'zovanie metabolicheskikh sredstv v kompleksnoi terapii ishemicheskoi bolezni serdtsa. Lechashchii vrach. 2012;3:77-82.
  27. Fragasso G, Piatti PM, Monti L et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146(5):E18.  doi:10.1016/s0002-8703(03)00415-0.
  28. Novikova M.V., Glezer M.G. Vliyanie trimetazidina na pokazateli sutochnogo monitorirovaniya elektrokardiogrammy i variabel'nosti serdechnogo ritma Kardiovaskulyarnaya profilaktika i terapiya. 2013;12(5):68-74.
  29. Statsenko M.E., Turkina S.V., Shilina N.N. Primenenie mel'doniya v kompleksnoi terapii serdechnoi nedostatochnosti v rannem postinfarktnom periode. Terapevticheskii arkhiv. 2014;4:30-35.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.